Literature DB >> 23358639

Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies.

Gloria Ikilezi1, Jane Achan, Abel Kakuru, Theodore Ruel, Edwin Charlebois, Tamara D Clark, Philip J Rosenthal, Diane Havlir, Moses R Kamya, Grant Dorsey.   

Abstract

In a recent randomized controlled trial, the use of protease inhibitor (PI)-based antiretroviral therapy (ART) was associated with a significantly lower incidence of malaria compared with non-nucleoside reverse transcriptase inhibitor-based ART in a cohort of human immunodeficiency virus-infected Ugandan children living in an area of high malaria transmission intensity. In this report, we compared the prevalence of asymptomatic parasitemia and gametocytemia using data from the same cohort. The prevalence of asymptomatic parasitemia did not differ between the two ART treatment arms. The PI-based arm was associated with a lower risk of gametocytemia at the time of diagnosis of malaria (6.6% versus 14.5%, P = 0.03) and during the 28 days after malaria diagnosis (3.4% versus 6.5%, P = 0.04). Thus, in addition to decreasing the incidence of malaria, the use of PI-based ART may lower transmission, as a result of a decrease in gametocytemia, in areas of high malaria transmission intensity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358639      PMCID: PMC3617863          DOI: 10.4269/ajtmh.12-0658

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  16 in total

1.  Antiretrovirals as antimalarial agents.

Authors:  Tina S Skinner-Adams; James S McCarthy; Donald L Gardiner; Petrina M Hilton; Katherine T Andrews
Journal:  J Infect Dis       Date:  2004-11-03       Impact factor: 5.226

2.  Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.

Authors:  Katherine T Andrews; David P Fairlie; Praveen K Madala; John Ray; David M Wyatt; Petrina M Hilton; Lewis A Melville; Lynette Beattie; Donald L Gardiner; Robert C Reid; Martin J Stoermer; Tina Skinner-Adams; Colin Berry; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Antimalarial asexual stage-specific and gametocytocidal activities of HIV protease inhibitors.

Authors:  Christopher L Peatey; Katherine T Andrews; Nina Eickel; Timothy MacDonald; Alice S Butterworth; Katharine R Trenholme; Donald L Gardiner; James S McCarthy; Tina S Skinner-Adams
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

4.  HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.

Authors:  Kimberly A Porter; Stephen R Cole; Joseph J Eron; Yu Zheng; Michael D Hughes; Shahin Lockman; Charles Poole; Tina S Skinner-Adams; Mina Hosseinipour; Doug Shaffer; Ronald D'Amico; Frederick K Sawe; Abraham Siika; Elizabeth Stringer; Judith S Currier; Tsungai Chipato; Robert Salata; James S McCarthy; Steven R Meshnick
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  In vitro activity of antiretroviral drugs against Plasmodium falciparum.

Authors:  Christian Nsanzabana; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

6.  Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study.

Authors:  J Whitworth; D Morgan; M Quigley; A Smith; B Mayanja; H Eotu; N Omoding; M Okongo; S Malamba; A Ojwiya
Journal:  Lancet       Date:  2000-09-23       Impact factor: 79.321

7.  Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.

Authors:  Sunil Parikh; Jiri Gut; Eva Istvan; Daniel E Goldberg; Diane V Havlir; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Antiretroviral treatment for children with peripartum nevirapine exposure.

Authors:  Paul Palumbo; Jane C Lindsey; Michael D Hughes; Mark F Cotton; Raziya Bobat; Tammy Meyers; Mutsawashe Bwakura-Dangarembizi; Benjamin H Chi; Philippa Musoke; Portia Kamthunzi; Werner Schimana; Lynette Purdue; Susan H Eshleman; Elaine J Abrams; Linda Millar; Elizabeth Petzold; Lynne M Mofenson; Patrick Jean-Philippe; Avy Violari
Journal:  N Engl J Med       Date:  2010-10-14       Impact factor: 91.245

9.  Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria.

Authors:  Richard O Otieno; Collins Ouma; John M Ong'echa; Christopher C Keller; Tom Were; Eliud N Waindi; Marian G Michaels; Richard D Day; John M Vulule; Douglas J Perkins
Journal:  AIDS       Date:  2006-01-09       Impact factor: 4.177

10.  Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.

Authors:  Grant Dorsey; Sarah Staedke; Tamara D Clark; Denise Njama-Meya; Bridget Nzarubara; Catherine Maiteki-Sebuguzi; Christian Dokomajilar; Moses R Kamya; Philip J Rosenthal
Journal:  JAMA       Date:  2007-05-23       Impact factor: 56.272

View more
  8 in total

1.  Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.

Authors:  Abel Kakuru; Jane Achan; Mary K Muhindo; Gloria Ikilezi; Emmanuel Arinaitwe; Florence Mwangwa; Theodore Ruel; Tamara D Clark; Edwin Charlebois; Philip J Rosenthal; Diane Havlir; Moses R Kamya; Jordan W Tappero; Grant Dorsey
Journal:  Clin Infect Dis       Date:  2014-04-23       Impact factor: 9.079

2.  The effect of antiretrovirals on Plasmodium falciparum liver stages.

Authors:  Charlotte V Hobbs; Patricia De La Vega; Scott R Penzak; Jillian Van Vliet; Urszula Krzych; Photini Sinnis; William Borkowsky; Patrick E Duffy
Journal:  AIDS       Date:  2013-06-19       Impact factor: 4.177

3.  Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.

Authors:  Theodore D Ruel; Abel Kakuru; Gloria Ikilezi; Florence Mwangwa; Grant Dorsey; Philip J Rosenthal; Edwin Charlebois; Diane Havlir; Moses Kamya; Jane Achan
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

4.  The epidemiological impact of HIV antiretroviral therapy on malaria in children.

Authors:  Scott Greenhalgh; Martial Ndeffo; Alison P Galvani; Sunil Parikh
Journal:  AIDS       Date:  2015-02-20       Impact factor: 4.177

5.  Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates.

Authors:  Charlotte V Hobbs; Saurabh Dixit; Scott R Penzak; Tejram Sahu; Sachy Orr-Gonzalez; Lynn Lambert; Katie Zeleski; Jingyang Chen; Jillian Neal; William Borkowsky; Yimin Wu; Patrick E Duffy
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria.

Authors:  George O Adjei; Bamenla Q Goka; Christabel C Enweronu-Laryea; Onike P Rodrigues; Lorna Renner; Abdul M Sulley; Michael Alifrangis; Insaf Khalil; Jorgen A Kurtzhals
Journal:  Malar J       Date:  2014-09-19       Impact factor: 2.979

7.  Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.

Authors:  Ronnie P Kasirye; Heiner Grosskurth; Paula Munderi; Jonathan Levin; Zacchaeus Anywaine; Andrew Nunn; Anatoli Kamali; Kathy Baisley
Journal:  AIDS       Date:  2017-02-20       Impact factor: 4.177

8.  Prevalence of Asymptomatic Parasitemia and Gametocytemia in HIV-Infected Children on Differing Antiretroviral Therapy.

Authors:  Charlotte V Hobbs; Erin E Gabriel; Portia Kamthunzi; Gerald Tegha; Jean Tauzie; Yonghua Li; Tiina Ilmet; Elena Artimovich; Jillian Neal; Ted Hall; Sunil Parikh; Brian Kirmse; Patrick Jean-Philippe; Jingyang Chen; William R Prescott; Paul Palumbo; Patrick E Duffy; William Borkowsky
Journal:  Am J Trop Med Hyg       Date:  2018-01       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.